NCT06902376
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06902376
Title XL092 and Cemiplimab in BRAF WT Thyroid Cancer (NEO-COMBATXL)
Acronym NEO-COMBATXL
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Dana Farber/Harvard Cancer Center NOT_YET_RECRUITING Boston Massachusetts 02215 United States Details
University of North Carolina at Chapel Hill RECRUITING Chapel Hill North Carolina 27599 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field